ARGX — ARGENX SE
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1697862 ·
Belgium
Last close
$959.49
Market Cap
$59.67B
52W High
$1072.75
52W Low
$661.85
ADV30
274,137
Next earnings
2026-10-22
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 1,515,000,000 | 1,370,000,000 | 494,000,000 | 472,000,000 | 10,032,000,000 | 3,584,000,000 | 1,615,000,000 |
| Mar 2026 | 1,298,000,000 | 1,177,000,000 | 394,000,000 | 366,000,000 | — | — | — |
| Dec 2025 | 1,287,877,000 | 1,138,190,000 | 359,557,000 | 532,950,000 | 8,682,698,000 | 3,491,289,000 | 1,359,606,000 |
| Sep 2025 | 1,126,961,000 | 1,017,535,000 | 349,970,000 | 344,258,000 | — | — | — |
Balance + Analyst (yfinance extras)
Retained Earnings
$558,000,000
Inventory
$371,000,000
Receivables
$1,941,000,000
ST Investments
$1,600,000,000
EBIT TTM
$1,751,168,000
Pretax Income TTM
$1,747,347,000
Interest Exp TTM
$3,821,000
Analysts
23
Yahoo Snapshot (yfinance, live)
Total Revenue
$5,315,468,800
EBITDA
$1,612,902,016
Free Cash Flow
$761,769,024
Enterprise Value
$1,533,905,600,512
Total Cash
$5,184,000,000
Total Debt
$47,000,000
Shares Out
62,187,771
Trailing EPS
$26.21
Book Value
$5.38
ROE
23.6%
ROA
11.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 4,153,482,000 | 1,054,615,000 | 1,292,035,000 | 8,682,698,000 | 1,359,606,000 | 7,323,092,000 | 685,192,000 |
| Dec 2024 | 2,190,231,000 | -17,844,000 | 833,040,000 | 6,202,522,000 | 704,239,000 | 5,498,283,000 | -82,747,000 |
| Dec 2023 | 1,226,316,000 | -420,638,000 | -295,053,000 | 4,542,458,000 | 444,951,000 | 4,097,507,000 | -420,327,000 |
| Dec 2022 | 410,746,000 | -723,919,000 | -709,594,000 | 3,134,261,000 | 320,562,000 | 2,813,699,000 | -862,807,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$34.51
Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $840.00 · spot: $959.49 · call volume: 620 · put volume: 359
Expected Move to 2026-12-18:
±$174.69
(18.21%) —
implied range
$784.80 –
$1134.18
· ATM straddle on $960.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MRNA | Moderna, Inc. | $79.40B | $198.88 | — |
| RVMD | Revolution Medicines, Inc. | $43.93B | $204.97 | — |
| BIIB | BIOGEN INC. | $33.63B | $227.60 | — |
| BNTX | BioNTech SE | $24.75B | $98.52 | — |
| GILD | GILEAD SCIENCES, INC. | $187.15B | $150.93 | — |
News headlines (Yahoo Finance, 1h cache)
Here's Exactly Why Wall Street Thinks Argenx Stock Could Soar 23% Over the Next 12 Months
2026-09-26 09:04 · Yahoo
European Equities Traded in the US as American Depositary Receipts Edge Lower in Thursday Trading
2026-09-24 15:10 · Yahoo
argenx (ENXTBR:ARGX) Stock Could Be Pricey Despite Strong Earnings Expectations
2026-09-24 03:22 · Yahoo
2 Wall Street Analysts Think Argenx Can Soar More Than 40%. Here's Why They're Right.
2026-09-20 10:12 · Yahoo
argenx announces results of Extraordinary General Meeting of Shareholders and appointment of Thomas M. Brakel and Khurem Farooq as Non-Executive Directors
2026-09-17 20:03 · Yahoo
BenchSci Announces Two-Year Enterprise Agreement with argenx to Advance AI-Driven Preclinical Drug Discovery
2026-09-02 12:00 · Yahoo
Argenx Has Delivered 18 Consecutive Quarters of Sales Growth -- but Is the Biotech Stock Still Underrated?
2026-09-02 09:04 · Yahoo
argenx to Present at Upcoming Investor Conferences
2026-09-01 05:00 · Yahoo
A single drug made Argenx one of the most valuable biotechs in Europe. Its new CEO is ready for the next act.
2026-08-28 13:16 · Yahoo
argenx (ENXTBR:ARGX) Stock Looks Rich Despite Its 210% Five Year Run
2026-08-28 08:20 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.